Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Sony Corporation (ADR) (SNE), The Walt Disney Company (DIS): Can IMAX Corporation (USA) (IMAX) Save “The Mortal Instruments”?

It’s hard to get a read on Wednesday’s release of Sony Corporation (ADR) (NYSE:SNE)‘s The Mortal Instruments: City of Bones. Will it be a late summer blockbuster? Will it be a costly flop? The movie could go either way, but it certainly seems as if it will fall on one extreme or the other.

We know what Sony Corporation (ADR) (NYSE:SNE) wants to convey. An unusual spot features the young actors as themselves making a crowded mall appearance. “Join the phenomenon,” goes the pitch. Show a massive crowd displaying signs of frenzied fandom for the largely obscure stars, and the swagger could be contagious.

Sony Corporation (ADR) (NYSE:SNE) has such high hopes for the release that it has already approved a second movie based on the popular urban fantasy book series. Cassandra Clare’s five-book series, with a sixth book due out next year, offers many of the elements — including monsters, teen angst, and supernatural whimsy — that helped propel Harry Potter, Hunger Games, and Twilight to multi-release success.

The book series hasn’t gained that kind of acclaim, but Sony Corporation (ADR) (NYSE:SNE)’s aiming high. The movie is even getting the super-sized IMAX Corporation (NYSE:IMAX) treatment.

Investing in remastering the movie to screen on IMAX Corporation (NYSE:IMAX)’s larger-than-life projection systems doesn’t come cheap, but it’s also no guarantee of success. Pacific Rim and The Lone Ranger were available as premium screenings on IMAX Corporation (NYSE:IMAX), and neither movie has cracked $100 million in domestic box-office receipts.

The Walt Disney Company (NYSE:DIS) conceded earlier this month that it may have to take a charge of as much as $190 million to write off The Lone Ranger as a flop. To be fair, its IMAX Corporation (NYSE:IMAX) release was limited to select international markets. It wasn’t screened domestically. But it serves as a cruel reminder that you can remaster a movie for IMAX, but that doesn’t mean the audiences will come.

Still, this isn’t a problem for IMAX Corporation (NYSE:IMAX). As it expands its installations, more studios are hopping on board. IMAX no longer lives and dies by the handful of movies made available as premium experiences. For every Cloud Atlas or A Good Day to Die Hard, there are more than enough blockbusters to keep the platform viable. In fact, before Pacific Rim, none of the four summer season releases put out before that through IMAX grossed less than $197 million in domestic ticket sales across all exhibitors.

In a few days it will be The Mortal Instruments hoping that IMAX is an instrument of immortality, but it will have to earn that success.

ETFs are also mortal instruments

To learn more about a few ETFs that have great promise for delivering profits to shareholders, check out The Motley Fool’s special free report “3 ETFs Set to Soar.” Just click here to access it now.

The article Can IMAX Save “The Mortal Instruments”? originally appeared on and is written by Rick Munarriz.

Longtime Fool contributor Rick Munarriz owns shares of Walt Disney (NYSE:DIS). The Motley Fool recommends and owns shares of IMAX and Walt Disney.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.